Novel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach (May 6, 2017)

Novel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach is organized by Rockpointe Corporation and would be held on May 6, 2017 at Chateau Elan Winery and Resort, Braselton, Georgia, United States Of America. This activity is intended for dermatologists, dermatology nurse practitioners/physician assistants, allergists, and other clinicians involved in the management of atopic dermatitis (AD). This CME Conference has been approved with a maximum of 1.0 AMA PRA Category 1 Credits.

Although atopic dermatitis (AD) is 2 to 3 times more prevalent than psoriasis, there have not been significant improvements in the management of this serious condition for decades. Patients and providers are dissatisfied and frustrated with the poor efficacy of topical agents and adverse events associated with broad-spectrum immunosuppressants.

An improved understanding of AD pathogenesis has led to the development of new treatments that target the Th2-polarized immune system, which plays a key role in the symptoms of AD and progression of the atopic march to more severe skin disease and respiratory allergic conditions. This CME activity will help allergists and dermatologists become more familiar with new treatment options for AD, and will discuss how emerging biomarkers in AD have the potential to enhance individualization of therapy, by targeting a patient's specific biological signatures, and help predict and monitor therapeutic response.